MARKET

JAN

JAN

JanOne Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.40
-0.04
-0.62%
After Hours: 6.45 +0.05 +0.78% 19:14 09/17 EDT
OPEN
6.43
PREV CLOSE
6.44
HIGH
6.64
LOW
6.33
VOLUME
60.91K
TURNOVER
--
52 WEEK HIGH
31.83
52 WEEK LOW
3.490
MARKET CAP
15.41M
P/E (TTM)
-1.6489
1D
5D
1M
3M
1Y
5Y
11 Industrials Stocks Moving In Monday's After-Market Session
Gainers Astrotech (NASDAQ:ASTC) shares moved upwards by 2.94% to $1.05 during Monday's after-market session. The company's market cap stands at $51.9 million.
Benzinga · 08/16 20:45
Akamai Technologies, Healthcare Trust of America, Change Healthcare among premarket losers' pack
Zymergen ZY -74% after forecasting no revenues this year, CEO exits Flora Growth (NASDAQ:FLGC) -15%. Tellurian TELL -12% on Q2 earnings release and to offer shares; size not determined. LivePerson LPSN -10% on Q2 earnings release. JanOne
Seekingalpha · 08/04 12:24
BRIEF-Janone Selects CPC Clinical Research As Trial Manager For Phase 2B Study Of Jan101
reuters.com · 07/22 15:20
JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic r...
PR Newswire · 07/22 13:45
BRIEF-Janone Readies Clinical Supply Of Lead Product Candidate Jan101 For Distribution To Phase 2B Trial Sites
reuters.com · 06/23 14:31
JanOne readies supply of JAN101 for distribution to phase 2b trial sites
JanOne ([[JAN]] -1.0%) announces that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating Peripheral Artery Disease ((PAD))
Seekingalpha · 06/23 14:27
JanOne Readying Clinical Supply of Potential Peripheral Artery Disease Treatment for Phase 2b Trial
MT Newswires · 06/23 14:25
JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that its clinical packaging partner Xerimis has received the bottled clinic...
PR Newswire · 06/23 14:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAN. Analyze the recent business situations of JanOne Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 209.63K
% Owned: 8.71%
Shares Outstanding: 2.41M
TypeInstitutionsShares
Increased
3
21.18K
New
5
107.24K
Decreased
1
14.94K
Sold Out
2
33.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Home Furnishings Retailers
-1.25%
Specialty Retailers
-0.32%
Key Executives
President
Edward Cameron
Chief Executive Officer/Director
Antonios Isaac
Chief Operating Officer
James Harper
Executive Vice President
Rachel Holmes
Vice President
Jeffrey Woloz
Independent Director
Timothy Matula
No Data
About JAN
JanOne Inc. is focused on developing treatments for diseases that cause severe pain. The Company operates through three segments Biotechnology, Recycling, and Technology. The Biotechnology segment is focused on the development of new solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment includes all fees charged and costs incurred for collecting, recycling, and installing appliances for utilities and other customers. The recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The technology segment designs wireless modules to connect devices to the Mobile Internet of Things (IoT) which contain location-based service (LBS) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information.

Webull offers kinds of Janone Inc stock information, including NASDAQ:JAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAN stock methods without spending real money on the virtual paper trading platform.